Loading stock data…
OKYO Pharma Limited (OKYO)
$1.53-0.04 (-2.55%)
Market ClosedLast close Sep 8
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OKYO Pharma Limited in the Healthcare sector is trading at $1.53 with a market capitalization of $82M. Wall Street consensus targets $8.33 (3 analysts), implying a +444.7% move over the next 12 months. The stock is currently near its 52-week low of $1.34, remaining 12.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +444.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
275,614
Recent News
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the
Sector Update: Healthcare Stocks Advance Tuesday Afternoon
Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Earnings Reports
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively tra
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report for the fiscal year ended March 31, 2026, outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate. The clinical-stage biopharmaceutical company said...
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week reported positive feedback from its Type D meeting with the US Food and Drug Administration (FDA), providing greater regulatory clarity as the company advances urcosimod toward a global Phase 3 pivotal study for neuropathic corneal pain...